{"transactions":[{"id":3405826,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":118033,"kind":"organization","name":"TYNDALL CAPITAL PARTNERS L P","position":1,"cik":"0001219314","reported_name":"TYNDALL CAPITAL PARTNERS L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-26T20:16:23.000Z","date":"2019-09-24","kind":"sale","acquired":false,"shares":16700,"price":1.19,"value":19873.0,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Tyndall Capital Partners, L.P. (\"Tyndall Capital\") is the general partner of Tyndall Partners, L.P. (\"Tyndall\"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any."}],"balance_after":616389,"source":{"system":"sec-edgar","filing":"0000905718-19-000789","document":"onconova_fm4sept242019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000090571819000789/onconova_fm4sept242019.xml","form_type":"4"}},{"id":3407199,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":118033,"kind":"organization","name":"TYNDALL CAPITAL PARTNERS L P","position":1,"cik":"0001219314","reported_name":"TYNDALL CAPITAL PARTNERS L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-24T20:08:25.000Z","date":"2019-09-23","kind":"sale","acquired":false,"shares":37242,"price":1.2343,"value":45967.8006,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Tyndall Capital Partners, L.P. (\"Tyndall Capital\") is the general partner of Tyndall Partners, L.P. (\"Tyndall\"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any."}],"balance_after":633089,"source":{"system":"sec-edgar","filing":"0000905718-19-000785","document":"onconova_fm4sept202019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000090571819000785/onconova_fm4sept202019.xml","form_type":"4"}},{"id":3407198,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":118033,"kind":"organization","name":"TYNDALL CAPITAL PARTNERS L P","position":1,"cik":"0001219314","reported_name":"TYNDALL CAPITAL PARTNERS L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-24T20:08:25.000Z","date":"2019-09-20","kind":"sale","acquired":false,"shares":75119,"price":1.6165,"value":121429.8635,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Tyndall Capital Partners, L.P. (\"Tyndall Capital\") is the general partner of Tyndall Partners, L.P. (\"Tyndall\"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any."}],"balance_after":670331,"source":{"system":"sec-edgar","filing":"0000905718-19-000785","document":"onconova_fm4sept202019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000090571819000785/onconova_fm4sept202019.xml","form_type":"4"}},{"id":3409085,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":118033,"kind":"organization","name":"TYNDALL CAPITAL PARTNERS L P","position":1,"cik":"0001219314","reported_name":"TYNDALL CAPITAL PARTNERS L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-20T20:05:11.000Z","date":"2019-09-18","kind":"sale","acquired":false,"shares":49995,"price":2.1005,"value":105014.4975,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Tyndall Capital Partners, L.P. (\"Tyndall Capital\") is the general partner of Tyndall Partners, L.P. (\"Tyndall\"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any."}],"balance_after":745450,"source":{"system":"sec-edgar","filing":"0000905718-19-000781","document":"onconova_fm4sept182019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000090571819000781/onconova_fm4sept182019.xml","form_type":"4"}},{"id":3415092,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":118033,"kind":"organization","name":"TYNDALL CAPITAL PARTNERS L P","position":1,"cik":"0001219314","reported_name":"TYNDALL CAPITAL PARTNERS L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-13T20:24:33.000Z","date":"2019-09-11","kind":"sale","acquired":false,"shares":1247,"price":2.7526,"value":3432.4922,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Tyndall Capital Partners, L.P. (\"Tyndall Capital\") is the general partner of Tyndall Partners, L.P. (\"Tyndall\"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any."}],"balance_after":795445,"source":{"system":"sec-edgar","filing":"0000905718-19-000775","document":"onconova_fm4sept112019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000090571819000775/onconova_fm4sept112019.xml","form_type":"4"}},{"id":3417738,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":118033,"kind":"organization","name":"TYNDALL CAPITAL PARTNERS L P","position":1,"cik":"0001219314","reported_name":"TYNDALL CAPITAL PARTNERS L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-11T20:16:20.000Z","date":"2019-09-09","kind":"sale","acquired":false,"shares":400,"price":2.765,"value":1106.0,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Tyndall Capital Partners, L.P. (\"Tyndall Capital\") is the general partner of Tyndall Partners, L.P. (\"Tyndall\"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any."}],"balance_after":796692,"source":{"system":"sec-edgar","filing":"0000905718-19-000773","document":"onconova_fm4sept092019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000090571819000773/onconova_fm4sept092019.xml","form_type":"4"}},{"id":3419706,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":118033,"kind":"organization","name":"TYNDALL CAPITAL PARTNERS L P","position":1,"cik":"0001219314","reported_name":"TYNDALL CAPITAL PARTNERS L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-09T20:10:48.000Z","date":"2019-09-06","kind":"sale","acquired":false,"shares":5015,"price":2.7825,"value":13954.2375,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Tyndall Capital Partners, L.P. (\"Tyndall Capital\") is the general partner of Tyndall Partners, L.P. (\"Tyndall\"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any."}],"balance_after":797092,"source":{"system":"sec-edgar","filing":"0000905718-19-000753","document":"onconova_fm4sept052019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000090571819000753/onconova_fm4sept052019.xml","form_type":"4"}},{"id":3419705,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":118033,"kind":"organization","name":"TYNDALL CAPITAL PARTNERS L P","position":1,"cik":"0001219314","reported_name":"TYNDALL CAPITAL PARTNERS L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-09T20:10:48.000Z","date":"2019-09-05","kind":"sale","acquired":false,"shares":400,"price":2.75,"value":1100.0,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Tyndall Capital Partners, L.P. (\"Tyndall Capital\") is the general partner of Tyndall Partners, L.P. (\"Tyndall\"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any."}],"balance_after":802107,"source":{"system":"sec-edgar","filing":"0000905718-19-000753","document":"onconova_fm4sept052019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000090571819000753/onconova_fm4sept052019.xml","form_type":"4"}},{"id":3463778,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":118033,"kind":"organization","name":"TYNDALL CAPITAL PARTNERS L P","position":1,"cik":"0001219314","reported_name":"TYNDALL CAPITAL PARTNERS L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-11T20:43:19.000Z","date":"2019-07-10","kind":"sale","acquired":false,"shares":2742,"price":2.807,"value":7696.794,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Tyndall Capital Partners, L.P. (\"Tyndall Capital\") is the general partner of Tyndall Partners, L.P. (\"Tyndall\"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any."}],"balance_after":802507,"source":{"system":"sec-edgar","filing":"0000905718-19-000596","document":"onconova_fm4jul92019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000090571819000596/onconova_fm4jul92019.xml","form_type":"4"}},{"id":3463777,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":118033,"kind":"organization","name":"TYNDALL CAPITAL PARTNERS L P","position":1,"cik":"0001219314","reported_name":"TYNDALL CAPITAL PARTNERS L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-11T20:43:19.000Z","date":"2019-07-09","kind":"sale","acquired":false,"shares":8185,"price":2.835,"value":23204.475,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Tyndall Capital Partners, L.P. (\"Tyndall Capital\") is the general partner of Tyndall Partners, L.P. (\"Tyndall\"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any."}],"balance_after":805249,"source":{"system":"sec-edgar","filing":"0000905718-19-000596","document":"onconova_fm4jul92019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000090571819000596/onconova_fm4jul92019.xml","form_type":"4"}},{"id":3474908,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":118033,"kind":"organization","name":"TYNDALL CAPITAL PARTNERS L P","position":1,"cik":"0001219314","reported_name":"TYNDALL CAPITAL PARTNERS L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-01T20:35:18.000Z","date":"2019-06-27","kind":"sale","acquired":false,"shares":1458,"price":3.4465,"value":5024.997,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Tyndall Capital Partners, L.P. (\"Tyndall Capital\") is the general partner of Tyndall Partners, L.P. (\"Tyndall\"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any."}],"balance_after":813434,"source":{"system":"sec-edgar","filing":"0000905718-19-000579","document":"onconova_fm4jun252019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000090571819000579/onconova_fm4jun252019.xml","form_type":"4"}},{"id":3477333,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":118033,"kind":"organization","name":"TYNDALL CAPITAL PARTNERS L P","position":1,"cik":"0001219314","reported_name":"TYNDALL CAPITAL PARTNERS L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-27T20:21:23.000Z","date":"2019-06-25","kind":"sale","acquired":false,"shares":1380,"price":3.3976,"value":4688.688,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Tyndall Capital Partners, L.P. (\"Tyndall Capital\") is the general partner of Tyndall Partners, L.P. (\"Tyndall\"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any."}],"balance_after":814892,"source":{"system":"sec-edgar","filing":"0000905718-19-000557","document":"onconova_fm4jun252019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000090571819000557/onconova_fm4jun252019.xml","form_type":"4"}},{"id":3952242,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":118033,"kind":"organization","name":"TYNDALL CAPITAL PARTNERS L P","position":1,"cik":"0001219314","reported_name":"TYNDALL CAPITAL PARTNERS L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock Purchase Warrant","published_at":"2018-05-01T20:12:44.000Z","date":"2018-04-27","kind":"purchase","acquired":true,"shares":10147058,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each warrant (\"Warrant\") is exercisable into 0.025 share of Series B Convertible Preferred Stock, par value $0.01 per share (\"Preferred Stock\") at an exercise price of $0.425 per 0.025 share of Preferred Stock. Each 0.025 share of Preferred Stock will be convertible into one share of common stock, par value $0.01 per share (the \"Common Stock\"). Onconova Therapeutics, Inc. (the \"Company\") does not currently have a sufficient number of authorized shares of Common Stock to cover the shares issuable upon the conversion of the Preferred Stock. As a result, before any shares of Preferred Stock can be converted, the Company must obtain stockholder approval of an amendment (the \"Charter Amendment\") to its certificate of incorporation, as amended, to sufficiently increase its authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each warrant (\"Warrant\") is exercisable into 0.025 share of Series B Convertible Preferred Stock, par value $0.01 per share (\"Preferred Stock\") at an exercise price of $0.425 per 0.025 share of Preferred Stock. Each 0.025 share of Preferred Stock will be convertible into one share of common stock, par value $0.01 per share (the \"Common Stock\"). Onconova Therapeutics, Inc. (the \"Company\") does not currently have a sufficient number of authorized shares of Common Stock to cover the shares issuable upon the conversion of the Preferred Stock. As a result, before any shares of Preferred Stock can be converted, the Company must obtain stockholder approval of an amendment (the \"Charter Amendment\") to its certificate of incorporation, as amended, to sufficiently increase its authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"10,147,058 Units purchased for $0.425 per Unit. Each Unit consists of one share of Common Stock and one Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Warrants are exercisable immediately and will expire on the eighteen (18) month anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that the Charter Amendment has been filed with the Secretary of State of the State of Delaware."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each warrant (\"Warrant\") is exercisable into 0.025 share of Series B Convertible Preferred Stock, par value $0.01 per share (\"Preferred Stock\") at an exercise price of $0.425 per 0.025 share of Preferred Stock. Each 0.025 share of Preferred Stock will be convertible into one share of common stock, par value $0.01 per share (the \"Common Stock\"). Onconova Therapeutics, Inc. (the \"Company\") does not currently have a sufficient number of authorized shares of Common Stock to cover the shares issuable upon the conversion of the Preferred Stock. As a result, before any shares of Preferred Stock can be converted, the Company must obtain stockholder approval of an amendment (the \"Charter Amendment\") to its certificate of incorporation, as amended, to sufficiently increase its authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Warrants are exercisable immediately and will expire on the eighteen (18) month anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that the Charter Amendment has been filed with the Secretary of State of the State of Delaware."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Tyndall Capital Partners, L.P. (\"Tyndall Capital\") is the general partner of Tyndall Partners, L.P. (\"Tyndall\"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any."}],"balance_after":10147058,"derivative":{"exercise_price":0.425,"exercise_date":"2018-04-27","underlying":"Series B Preferred Stock","underlying_shares":253677},"source":{"system":"sec-edgar","filing":"0000905718-18-000415","document":"onconova_fm4apr272018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000090571818000415/onconova_fm4apr272018.xml","form_type":"4"}},{"id":3952241,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":118033,"kind":"organization","name":"TYNDALL CAPITAL PARTNERS L P","position":1,"cik":"0001219314","reported_name":"TYNDALL CAPITAL PARTNERS L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-01T20:12:44.000Z","date":"2018-04-27","kind":"purchase","acquired":true,"shares":10147058,"price":0.425,"value":4312499.65,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Tyndall Capital Partners, L.P. (\"Tyndall Capital\") is the general partner of Tyndall Partners, L.P. (\"Tyndall\"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any."}],"balance_after":12244080,"source":{"system":"sec-edgar","filing":"0000905718-18-000415","document":"onconova_fm4apr272018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000090571818000415/onconova_fm4apr272018.xml","form_type":"4"}},{"id":4066306,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":118033,"kind":"organization","name":"TYNDALL CAPITAL PARTNERS L P","position":1,"cik":"0001219314","reported_name":"TYNDALL CAPITAL PARTNERS L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock Purchase Warrant","published_at":"2018-02-13T00:12:24.000Z","date":"2018-02-08","kind":"purchase","acquired":true,"shares":1100000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each warrant (\"Warrant\") is exercisable into 0.1 share of Series A Convertible Preferred Stock, par value $0.01 per share (\"Preferred Stock\") at an exercise price of $1.01 per 0.1 share of Preferred Stock. Each 0.1 share of Preferred Stock will be convertible into one share of common stock, par value $0.01 per share (the \"Common Stock\"). The Company does not currently have a sufficient number of authorized shares of Common Stock to cover the shares issuable upon the conversion of Series A Preferred Stock. As a result, before any shares of Preferred Stock can be converted, the Issuer must obtain stockholder approval of an amendment (the \"Charter Amendment\") to its Tenth Amended and Restated Certificate of Incorporation, as amended, to sufficiently increase its authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each warrant (\"Warrant\") is exercisable into 0.1 share of Series A Convertible Preferred Stock, par value $0.01 per share (\"Preferred Stock\") at an exercise price of $1.01 per 0.1 share of Preferred Stock. Each 0.1 share of Preferred Stock will be convertible into one share of common stock, par value $0.01 per share (the \"Common Stock\"). The Company does not currently have a sufficient number of authorized shares of Common Stock to cover the shares issuable upon the conversion of Series A Preferred Stock. As a result, before any shares of Preferred Stock can be converted, the Issuer must obtain stockholder approval of an amendment (the \"Charter Amendment\") to its Tenth Amended and Restated Certificate of Incorporation, as amended, to sufficiently increase its authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"1,100,000 Units purchased for $1.01 per Unit.  Each Unit consists of one share of Common Stock and one Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Warrants are exercisable immediately and will expire on the later of (i) the one-year anniversary of the date (the \"Charter Amendment Date\") on which Issuer publicly announces through the filing of a Current Report on Form 8-K that the amendment to their certificate of incorporation to sufficiently increase their authorized shares of Common Stock to cover the conversion of all outstanding shares of Series A Preferred Stock into Common Stock has been filed with the Secretary of State of the State of Delaware and (ii) the earlier of (A) the one-month anniversary of the date on which Issuer publicly releases their top-line results of the INSPIRE Pivotal phase 3 that compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each warrant (\"Warrant\") is exercisable into 0.1 share of Series A Convertible Preferred Stock, par value $0.01 per share (\"Preferred Stock\") at an exercise price of $1.01 per 0.1 share of Preferred Stock. Each 0.1 share of Preferred Stock will be convertible into one share of common stock, par value $0.01 per share (the \"Common Stock\"). The Company does not currently have a sufficient number of authorized shares of Common Stock to cover the shares issuable upon the conversion of Series A Preferred Stock. As a result, before any shares of Preferred Stock can be converted, the Issuer must obtain stockholder approval of an amendment (the \"Charter Amendment\") to its Tenth Amended and Restated Certificate of Incorporation, as amended, to sufficiently increase its authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Warrants are exercisable immediately and will expire on the later of (i) the one-year anniversary of the date (the \"Charter Amendment Date\") on which Issuer publicly announces through the filing of a Current Report on Form 8-K that the amendment to their certificate of incorporation to sufficiently increase their authorized shares of Common Stock to cover the conversion of all outstanding shares of Series A Preferred Stock into Common Stock has been filed with the Secretary of State of the State of Delaware and (ii) the earlier of (A) the one-month anniversary of the date on which Issuer publicly releases their top-line results of the INSPIRE Pivotal phase 3 that compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Tyndall Capital Partners, L.P. (\"Tyndall Capital\") is the general partner of Tyndall Partners, L.P. (\"Tyndall\"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any."}],"balance_after":1100000,"derivative":{"exercise_price":1.01,"exercise_date":"2018-02-08","underlying":"Series A Preferred Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0000905718-18-000125","document":"onconova_fm4feb82018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000090571818000125/onconova_fm4feb82018.xml","form_type":"4"}},{"id":4066305,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":118033,"kind":"organization","name":"TYNDALL CAPITAL PARTNERS L P","position":1,"cik":"0001219314","reported_name":"TYNDALL CAPITAL PARTNERS L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-02-13T00:12:24.000Z","date":"2018-02-08","kind":"purchase","acquired":true,"shares":1100000,"price":1.01,"value":1111000.0,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Tyndall Capital Partners, L.P. (\"Tyndall Capital\") is the general partner of Tyndall Partners, L.P. (\"Tyndall\"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any."}],"balance_after":2097022,"source":{"system":"sec-edgar","filing":"0000905718-18-000125","document":"onconova_fm4feb82018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000090571818000125/onconova_fm4feb82018.xml","form_type":"4"}},{"id":4346762,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":118033,"kind":"organization","name":"TYNDALL CAPITAL PARTNERS L P","position":1,"cik":"0001219314","reported_name":"TYNDALL CAPITAL PARTNERS L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-04-24T22:06:51.000Z","date":"2017-04-21","kind":"grant","acquired":true,"shares":476190,"price":2.1,"value":999999.0,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As of April 21, 2017, Tyndall Partners, L.P., a Delaware limited partnership (\"Tyndall\"), held 997,022 shares of common stock, par value $0.01 per share (\"Shares\"), and warrants to purchase up to 390,624 Shares. Tyndall Capital Partners, L.P. is the general partner of Tyndall Capital Partners L.P. (\"Tyndall Capital\"), and possesses the sole power to vote and the sole power to direct the disposition of all Shares and other securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any"}],"balance_after":997022,"source":{"system":"sec-edgar","filing":"0000905718-17-000493","document":"tyndall_fm4apr212017.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000090571817000493/tyndall_fm4apr212017.xml","form_type":"4"}}]}